Jason Kelly posits that since therapeutics currently dominate 90% of the cell engineering market, offshoring drug discovery to China means ceding control of the entire strategic field of genetic engineering, which has far broader future applications.
The 2026 biotech IPO market is outpacing 2025, but the focus on companies with late-stage clinical data, like Cardigan, indicates a mature and rational market rather than the speculative, preclinical bubbles of the past.
Jason Kelly compares modern lab automation to the advent of electronic calculators. He argues that by making R&D more efficient and increasing the ROI on scientists' ideas, automation will ultimately expand the number of high-value research jobs, not reduce them.
Biohaven's Telde-Cropop Alpha tackles a key drawback of GLP-1 drugs: significant muscle mass loss alongside fat loss. By targeting myostatin, the drug aims to preserve or increase muscle while patients lose weight, addressing a major concern for long-term health and body composition.
According to the Endpoints Biopharma Sentiment Index, the finance community's outlook has surged to 120, well above the 100 average. This is significantly more bullish than the sentiment of biotech CEOs and CDMOs, whose outlooks are still tracking below 100 despite improving.
After positive Phase 2 data, Apogee Therapeutics secured up to $1.3B in non-dilutive financing from Blackstone Life Sciences. This creative deal, involving a synthetic royalty and debt, represents a powerful alternative to traditional follow-on equity offerings for capitalizing clinical progress.
Jason Kelly argues against the "free market" view of pharma, noting U.S. consumers generate 70% of global drug profits. This market power means the U.S. is effectively paying for the R&D that builds up China's strategic biotech industry, a national security concern.
GlaxoSmithKline's Bepirovirsen achieved a ~19% functional cure rate for Hepatitis B in Phase 3 trials. This represents a significant advance over existing low single-digit cure rates and may revive investor and scientific interest in a challenging disease area.
Following the departure of commissioner Marty McCary, the FDA seems to be taking a more predictable stance. Several companies that previously received Complete Response Letters, such as Reflemunov and Outlook, are now successfully resubmitting their applications, signaling a potential thaw in industry-regulator relations.